Amgen says obesity drug caused up to 20% weight loss

Amgen's obesity drug causes up to 20% weight loss, trial data weighs on shares
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of people who were overweight or obese, it said on Tuesday. The drugmaker's shares, however,
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year in a critical mid-stage trial. The company said it did not observe a plateau, which indicates the potential for further weight loss beyond 52 weeks.
Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could be remain
Amgen drug leads to up to 20% weight loss in trial
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.
Sharp increase in number of illegal weight loss drugs seized
HPRA warns of risks of illegal, counterfeit versions of drugs such as Ozempic and Wegovy, saying they pose ‘significant risk’
Amgen Drug Cut Weight in Closely Watched Study
The news sent Amgen shares gyrating in premarket trading, falling as much as 10%, as investors parsed the company’s announcement and awaited more details from
Amgen's obesity drug cuts weight by up to 20%, trial data drags down shares
Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long mid-stage trial, data that missed lofty investor expectations and sent the shares down 8% before the bell on Tuesday.
Amgen’s stock slides 7.8% premarket after weight-loss drug data lags analyst expectations
Amgen Inc.’s stock tumbled 7.8% in early trade Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting the treatment to achieve an average weight loss of about 20% to 24% after one year of treatment,
Medicare proposes covering weight-loss drugs, teeing up clash with RFK Jr.
The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden ...
Biden wants Medicare, Medicaid to cover pricey weight-loss drugs such as Wegovy
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid ...
Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese Americans
Millions of Americans would be eligible to have costly weight-loss drugs like Wegovy or Ozempic covered by Medicare or ...
Weight-Loss Drugs Like Ozempic Would Be Covered By Medicare And Medicaid Under Biden Plan
Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden ...
Weight-loss drugmakers’ stocks get a boost from new Biden proposal on drug coverage, but will it hold up?
The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...
Biden seeks Medicare and Medicaid coverage of popular but costly weight-loss drugs for millions of Americans
WASHINGTON -- Biden seeks Medicare and Medicaid coverage of popular but costly weight-loss drugs for millions of Americans.
Is a ‘Liquid Diet’ good for weight loss? Tips to follow this diet
Explore the effectiveness of liquid diets for weight loss. Learn about their benefits, potential downsides, and essential ...
West Virginia ends promising subsidy program for GLP-1 weight loss drugs
In 2020, West Virginia launched a pilot program to subsidize GLP-1 drugs for public employees, but the program was shuttered ...